Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas
Status: Enrolling
Updated:  8/31/2015
M D Anderson Cancer Center
mi
from
Houston, TX
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas
Status: Enrolling
Updated: 8/31/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas
Status: Enrolling
Updated:  8/31/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas
Status: Enrolling
Updated: 8/31/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)
Status: Enrolling
Updated:  8/31/2015
North Shore University Hospital
mi
from
Manhasset, NY
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)
Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)
Status: Enrolling
Updated: 8/31/2015
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated:  9/2/2015
University of Chicago
mi
from
Chicago, IL
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated: 9/2/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated:  9/2/2015
NorthShore University Health System
mi
from
Evanston, IL
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated: 9/2/2015
NorthShore University Health System
mi
from
Evanston, IL
Click here to add this to my saved trials
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated:  9/2/2015
University of Michigan
mi
from
Ann Arbor, MI
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated: 9/2/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated:  9/2/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated: 9/2/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated:  9/2/2015
Waukesha health care
mi
from
Waukesha, WI
Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme
Avastin and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme: A Phase II Study
Status: Enrolling
Updated: 9/2/2015
Waukesha health care
mi
from
Waukesha, WI
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
University of Maryland School of Medicine
mi
from
Baltimore, MD
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
University of Maryland School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
Cleveland Clinic
mi
from
Cleveland, OH
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
Kettering Medical Center
mi
from
Kettering, OH
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
Kettering Medical Center
mi
from
Kettering, OH
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
University of Wisconsin
mi
from
Madison, WI
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
City of Hope
mi
from
Duarte, CA
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
City of Hope
mi
from
Duarte, CA
Click here to add this to my saved trials
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated:  9/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
Status: Enrolling
Updated: 9/8/2015
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme
A Double-Blinded Randomized Placebo-Controlled Trial Exploring the Efficacy of Oral ARginine Supplementation to Improve Cellular Immune Function in Patients With Glioblastoma Multiforme
Status: Enrolling
Updated:  9/10/2015
Inova Outpatient Surgery Clinic and Inova Fairfax Hospital
mi
from
Fairfax, VA
Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme
A Double-Blinded Randomized Placebo-Controlled Trial Exploring the Efficacy of Oral ARginine Supplementation to Improve Cellular Immune Function in Patients With Glioblastoma Multiforme
Status: Enrolling
Updated: 9/10/2015
Inova Outpatient Surgery Clinic and Inova Fairfax Hospital
mi
from
Fairfax, VA
Click here to add this to my saved trials
Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
Phase 1, Open-Label, Single-Arm, Clinical and Metabolomics Study of Dichloroacetate (DCA) in Adults With Recurrent Malignant Brain Tumors
Status: Enrolling
Updated:  9/18/2015
University of Florida
mi
from
Gainesville, FL
Study of the Safety and Efficacy of Dichloroacetate (DCA) in Glioblastoma and Other Recurrent Brain Tumors
Phase 1, Open-Label, Single-Arm, Clinical and Metabolomics Study of Dichloroacetate (DCA) in Adults With Recurrent Malignant Brain Tumors
Status: Enrolling
Updated: 9/18/2015
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.
Status: Enrolling
Updated:  9/21/2015
Allegheny General Hospital
mi
from
Pittsburgh, PA
Safety Study of Aminolevulinic Acid (ALA) to Improve Visibility of Brain Tumors During Surgery
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Primary Glial Neoplasms of the Brain.
Status: Enrolling
Updated: 9/21/2015
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
Status: Enrolling
Updated:  9/24/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
A Pilot Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
Status: Enrolling
Updated: 9/24/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study
Status: Enrolling
Updated:  9/25/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
Combination of Targeted I -3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients With Relapsed or Refractory Neuroblastoma: A Phase I Study
Status: Enrolling
Updated: 9/25/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Gene Therapy for the Treatment of Brain Tumors
Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction With the Thymidine Kinase Gene and Intravenous Ganciclovir
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Gene Therapy for the Treatment of Brain Tumors
Gene Therapy for the Treatment of Brain Tumors Using Intra-Tumoral Transduction With the Thymidine Kinase Gene and Intravenous Ganciclovir
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Informed Consent in Pediatric Cancer Trials
Informed Consent in Pediatric Phase I Cancer Trials
Status: Enrolling
Updated:  9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Informed Consent in Pediatric Cancer Trials
Informed Consent in Pediatric Phase I Cancer Trials
Status: Enrolling
Updated: 9/26/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Informed Consent in Pediatric Cancer Trials
Informed Consent in Pediatric Phase I Cancer Trials
Status: Enrolling
Updated:  9/26/2015
Cleveland Clinic Foundation Childrens Hospital
mi
from
Cleveland, OH
Informed Consent in Pediatric Cancer Trials
Informed Consent in Pediatric Phase I Cancer Trials
Status: Enrolling
Updated: 9/26/2015
Cleveland Clinic Foundation Childrens Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated:  9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
Status: Enrolling
Updated: 9/28/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study
Status: Enrolling
Updated:  9/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study
Status: Enrolling
Updated: 9/28/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study
Status: Enrolling
Updated:  9/28/2015
University of Virginia Cancer Center
mi
from
Charlottesville, VA
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Trial of RO4929097 in Combination With Standard Radiotherapy and Temozolomide for Newly Diagnosed Malignant Glioma: A Pharmacokinetic and Pharmacodynamic Study
Status: Enrolling
Updated: 9/28/2015
University of Virginia Cancer Center
mi
from
Charlottesville, VA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
mi
from
Fairbanks, AK
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
CCOP - Western Regional, Arizona
mi
from
Phoenix, AZ
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
CCOP - Western Regional, Arizona
mi
from
Phoenix, AZ
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
CCOP - Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
University of California Davis Cancer Center
mi
from
Sacramento, CA
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
University of California Davis Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
University of Colorado Cancer Center at University of Colorado Health Sciences Center
mi
from
Aurora, CO
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
University of Colorado Cancer Center at University of Colorado Health Sciences Center
mi
from
Aurora, CO
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
St. Anthony Central Hospital
mi
from
Denver, CO
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
St. Anthony Central Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Denver Health Medical Center
mi
from
Denver, CO
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Denver Health Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Veterans Affairs Medical Center - Denver
mi
from
Denver, CO
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Veterans Affairs Medical Center - Denver
mi
from
Denver, CO
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Montrose Memorial Hospital Cancer Center
mi
from
Montrose, CO
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Montrose Memorial Hospital Cancer Center
mi
from
Montrose, CO
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
St. Anthony North Hospital
mi
from
Westminster, CO
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
St. Anthony North Hospital
mi
from
Westminster, CO
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Exempla Lutheran Medical Center
mi
from
Wheat Ridge, CO
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Exempla Lutheran Medical Center
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
M.D. Anderson Cancer Center at Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
North Idaho Cancer Center
mi
from
Coeur d'Alene, ID
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
North Idaho Cancer Center
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Rush-Copley Cancer Care Center
mi
from
Aurora, IL
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
St. Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Graham Hospital
mi
from
Canton, IL
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Graham Hospital
mi
from
Canton, IL
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Memorial Hospital
mi
from
Carthage, IL
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
University of Illinois Medical Center
mi
from
Chicago, IL
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
University of Illinois Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated:  9/28/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma
Phase II Study of Hydroxyurea for Unresectable Meningioma
Status: Enrolling
Updated: 9/28/2015
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials